|
| Ipratropium Chemical Properties |
Melting point | 230-232°C | RTECS | YM3700000 | storage temp. | Inert atmosphere,Room Temperature | solubility | H2O: 10 mg/mL | form | powder | color | white | Water Solubility | Freely soluble | Stability: | Stable. Incompatible with strong oxidizing agents. | CAS DataBase Reference | 22254-24-6(CAS DataBase Reference) |
Hazard Codes | Xn | Risk Statements | 20/22-36 | Safety Statements | 26 | WGK Germany | 3 | Toxicity | LD50 in male, female mice (mg/kg): 1001, 1083 orally; 12.29, 14.97 i.v.; 300, 340 s.c.; LD50 in male, female rats (mg/kg): 1663, 1779 orally; 15.89, 15.70 i.v. (Sarafana) |
| Ipratropium Usage And Synthesis |
Description | Ipratropium belongs to the family of medicines known as bronchodilators. Bronchodilators are medicines that are breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. | Uses | Ipratropium is used to help control the symptoms of lung diseases, such as asthma, chronic bronchitis, and emphysema. It is also used to treat air flow blockage and prevent the worsening of chronic obstructive pulmonary disease (COPD). | Side effects | Ipratropium may induce various side effects, which should be reported to your doctor if they persist or become severe. These may include dizziness, nausea, heartburn, constipation, dry mouth, difficulty urinating, painful urination, frequent urge to urinate, and back pain. Additionally, some side effects can be serious and require immediate medical attention. These include the development of a rash, hives, itching, swelling of the eyes, face, lips, tongue, throat, hands, feet, ankles, or lower legs, hoarseness, difficulty breathing or swallowing, rapid or irregular heartbeat, and chest pain. |
| Ipratropium Preparation Products And Raw materials |
|